{"protocolSection":{"identificationModule":{"nctId":"NCT00531947","orgStudyIdInfo":{"id":"S9303-P0605"},"organization":{"fullName":"Somerset Pharmaceuticals","class":"INDUSTRY"},"briefTitle":"Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression","officialTitle":"A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible Dose Study of the Safety and Efficacy of EMSAM in Adolescents With Major Depression"},"statusModule":{"statusVerifiedDate":"2013-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-07"},"primaryCompletionDateStruct":{"date":"2010-10","type":"ACTUAL"},"completionDateStruct":{"date":"2010-10","type":"ACTUAL"},"studyFirstSubmitDate":"2007-09-18","studyFirstSubmitQcDate":"2007-09-18","studyFirstPostDateStruct":{"date":"2007-09-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-12-27","resultsFirstSubmitQcDate":"2013-05-16","resultsFirstPostDateStruct":{"date":"2013-06-26","type":"ESTIMATED"},"lastUpdateSubmitDate":"2013-12-12","lastUpdatePostDateStruct":{"date":"2014-01-15","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Somerset Pharmaceuticals","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The primary purpose of your participation in this study is to help answer the following research question: Whether 12-week administration of EMSAM (selegiline transdermal system) is safe and effective for the treatment of adolescents (aged 12 through 17 years) with Major Depressive Disorder (MDD).","detailedDescription":"• Assess the safety and efficacy of EMSAM (selegiline transdermal system) versus placebo in adolescents (aged 12 through 17 years) who meet criteria for Major Depressive Disorder (MDD) without psychotic features, single or recurrent"},"conditionsModule":{"conditions":["Major Depressive Disorder"],"keywords":["Mental Health","Adolescents","Major Depressive Disorder","Depression","Adolescent Depression","Pediatric Depression"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":308,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"EMSAM","type":"EXPERIMENTAL","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg","interventionNames":["Drug: Selegiline Transdermal System"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo Selegiline Transdermal System 6, 9 or 12","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Selegiline Transdermal System","description":"EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study","armGroupLabels":["EMSAM"],"otherNames":["EMSAM"]},{"type":"DRUG","name":"Placebo","description":"Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study","armGroupLabels":["Placebo"],"otherNames":["Matching Placebo Transdermal System"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"CDRS-R Total Score (Child) (mITT w/LOCF Population) Week 12","description":"A summary of the primary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score, as reported by the Child, at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time.\n\nCDRS-R total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior.","timeFrame":"baseline and 12 Weeks"}],"secondaryOutcomes":[{"measure":"CGI-S - Week 12 (mITT w/LOCF Population)","description":"A summary of the Clinical Global Impression of Severity (CGI-S) at baseline and Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF. The CGI-s is the clinician's assessment of severity of illness (depression). Scores range from 1(minimum) to 7(maximum). A lower score indicates lower illness severity, a higher score indicates higher levels of illness severity.","timeFrame":"Baseline and 12 Weeks"},{"measure":"CGI-C - Week 12 (mITT w/LOCF Population)","description":"A summary of the Clinicians Global Impression of Change (CGI-C) Score at Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF. The CGI-c assesses the overall change in the severity of illness (depression). The clinician rates the subject's change based on a bipolar scale from 1(minimum; \"Very much improved\") to 7(maximum; \"Very much worse\"). A lower score indicates lower levels of depression as compared to baseline, a higher score indicates higher levels of depression as compared to baseline. A score of 4 (\"Unchanged\") indicates no change in illness compared to baseline. The scale is not calculated as a statistical change score; the clinician rates their impression of change overall.","timeFrame":"12 Weeks"},{"measure":"CGI-C Percent Responders (mITT w/LOCF Population)","description":"A summary of the CGI-C percent responders at Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF. CGI-C responders were defined as a score of 1 or 2 at the end of the study. A non-responder was defined as a score of ≥3 at end of study. Maximum score is 100%.","timeFrame":"12 Weeks"},{"measure":"CDRS-R Total Score (Parent/Other) Week 12 (mITT w/LOCF Population)","description":"A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Parent/Other), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time.\n\nCDRS-R (Parent/Other) total raw scores range from 14 (minimum) 94 (maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. One subscale is summed to calculate a total score: Evaluated Symptom Area. Ratings of Observed Nonverbal Behavior subscale is not included in Parent/Other total calculation.","timeFrame":"Baseline and 12 Weeks"},{"measure":"CDRS-R Total Score (Best Description) Week 12 (mITT w/LOCF Population)","description":"A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Best Description), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time.\n\nBest Description ratings are used when ratings based on interviews with different sources (e.g., child, parent, other ratings) differ for a particular symptom. The evaluator must determine which of these ratings most accurately represents the current affective functioning of the child, and circle that rating in the Best Description of Child Column.\n\nCDRS-R (Best Description)total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior.","timeFrame":"12 Weeks"},{"measure":"CDRS-R Total Score (Child) Week 12 (mITT w/OC Population)","description":"A summary of the secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Child), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population with observed cases (w/OC).\n\nCDRS-R (Child) total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior.","timeFrame":"12 Weeks"},{"measure":"CDRS-R Total Score (Parent/Other) Week 12 (mITT w/OC Population)","description":"A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Parent/Other), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population with observed cases (w/OC).\n\nCDRS-R (Parent/Other) total raw scores range from 14 (minimum) 94 (maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. One subscale is summed to calculate a total score: Evaluated Symptom Area. Ratings of Observed Nonverbal Behavior subscale is not included in Parent/Other total calculation.","timeFrame":"12 Weeks"},{"measure":"CDRS-R Total Score (Best Description) Week 12 (mITT w/OC Population)","description":"A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Best Description), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with observed cases (w/OC).\n\nBest Description ratings are used when ratings based on interviews with different sources (e.g., child, parent, other ratings) differ for a particular symptom area. The evaluator must determine which of these ratings most accurately represents the current affective functioning of the child, and circle that rating in the Best Description of Child Column.\n\nCDRS-R (Best Description) total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior.","timeFrame":"12 Weeks"},{"measure":"Physical Examination (Screening vs. EOS)","description":"Number of physical examination findings that were normal at screening, but abnormal at end of study are presented. Four subjects receiving placebo and four subjects receiving EMSAM had abnormal findings on physical examination at the end of study that were normal at screening.","timeFrame":"12 Weeks"},{"measure":"Urinalysis (Change From Baseline)","description":"A summary of a secondary safety outcome measure, Urinalysis (Change from Baseline), by treatment assigned, is shown for the safety population. Mean changes from baseline are provided for PH and specific gravity.","timeFrame":"12 Weeks"},{"measure":"Vital Signs-Heart Rate (Change From Baseline)","description":"Summary mean change in heart rate measured in beats per minute (beats/min or BPM) (supine, standing, and orthostatic change)results for all subjects are presented.","timeFrame":"12 Weeks"},{"measure":"Vital Signs-Blood Pressure (Change From Baseline)","description":"Summary mean change in blood pressure (systolic/diastolic) measured in millimeters of mercury (mmHg) (supine, standing, and orthostatic change)results for all subjects are presented.","timeFrame":"12 Weeks"},{"measure":"12 Lead ECG (Change From Baseline)","description":"A summary of a secondary safety outcome measure, 12 Lead electrocardiogram (ECG) (Change from Baseline) measured in milliseconds (msec), by treatment assigned, is shown for the safety population. Mean change from Baseline in PR interval, QRS duration, QT interval, and QTc (Bazett and Fridericia corrections) interval are presented.","timeFrame":"12 Weeks"},{"measure":"12 Lead ECG (Change From Baseline)Ventricular Heart Rate","description":"A summary of a secondary safety outcome measure, 12 Lead electrocardiogram (ECG) (Change from Baseline)Ventricular Heart Rate measured in beats per minute(beats/min or BPM), by treatment assigned, is shown for the safety population. Mean change from baseline is presented.","timeFrame":"12 Weeks"},{"measure":"Hematology - White Blood Cell (WBC) (Change From Baseline)","description":"A summary of a secondary safety outcome measure, Hematology (Change from Baseline), by treatment assigned, is shown for the safety population. Mean change from Baseline in ABS BASOPHILS (X10\\^9/L), ABS EOSINOPHILS (X10\\^9/L), ABS LYMPHOCYTES (X10\\^9/L), ABS MONOCYTES (X10\\^9/L), and ABS NEUTROPHILS (X10\\^9/L) are presented.","timeFrame":"12 Weeks"},{"measure":"Hematology - Hematocrit (Change From Baseline)","description":"A summary of a secondary safety outcome measure, Hematology - Hematocrit(HCT)(Change from Baseline), by treatment assigned, is shown for the safety population.","timeFrame":"12 Weeks"},{"measure":"Hematology - Hemoglobin (Change From Baseline)","description":"A summary of a secondary safety outcome measure, Hematology - Hemoglobin(HGB)(Change from Baseline), by treatment assigned, is shown for the safety population.","timeFrame":"12 Weeks"},{"measure":"Hematology - Red Blood Cell (Change From Baseline)","description":"A summary of a secondary safety outcome measure, Hematology - Red Blood Cell (RBC)(Change from Baseline), by treatment assigned, is shown for the safety population.","timeFrame":"12 Weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male / Female outpatients 12 to 17 years of age diagnosed with Major Depressive Disorder (MDD). (Must have a Children's Depression Rating Scale-Revised \\[CDRS-R\\] with a total score of at least 45 at screening.)\n* Female patients must test negative on a pregnancy at visit 1.\n* Weight and height must be greater than the 10th percentile according to age and height,\n* Assent and consent must be given.\n\nExclusion Criteria:\n\n* Have a serious or unstable medical illness, psychological condition, clinically significant laboratory or ECG result, hypersensitivity to selegiline, or any other condition that in the opinion of the investigator would compromise participation in the study or be likely to lead to hospitalization during the course of the study.\n* Have a current or previous diagnosis of bipolar disorder, psychotic depression, schizophrenia or other psychotic disorder, anorexia, bulimia, obsessive compulsive disorder, pervasive development disorder or borderline personality disorder, as determined by the investigator.\n* Have a risk of suicide\n* Female patients who are either pregnant, nursing or have recently given birth.\n* Use of any protocol prohibited medications or substances.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Thomas Hochadel, Pharm.D.","affiliation":"Cognitive Research Corporation","role":"STUDY_DIRECTOR"},{"name":"Melissa L Goodhead","affiliation":"Somerset Pharmaceuticals","role":"STUDY_CHAIR"}],"locations":[{"facility":"Dr. Nelson Handal","city":"Dothan","state":"Alabama","country":"United States","geoPoint":{"lat":31.22323,"lon":-85.39049}},{"facility":"Dr. Mohammed Bari","city":"National City","state":"California","country":"United States","geoPoint":{"lat":32.67811,"lon":-117.0992}},{"facility":"Dr. Michael McManus","city":"San Diego","state":"California","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Dr. Elias Sarkis","city":"Gainesville","state":"Florida","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"facility":"Dr. Scott Segal","city":"North Miami","state":"Florida","country":"United States","geoPoint":{"lat":25.89009,"lon":-80.18671}},{"facility":"Dr. Mary Stedman","city":"Tampa","state":"Florida","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Dr. Irving Kolin","city":"Winter Park","state":"Florida","country":"United States","geoPoint":{"lat":28.6,"lon":-81.33924}},{"facility":"Dr. Rory Murphy","city":"Overland Park","state":"Kansas","country":"United States","geoPoint":{"lat":38.98223,"lon":-94.67079}},{"facility":"Dr. Andrew Sediloo","city":"Owensboro","state":"Kentucky","country":"United States","geoPoint":{"lat":37.77422,"lon":-87.11333}},{"facility":"Dr. Bruce Waslick","city":"Springfield","state":"Massachusetts","country":"United States","geoPoint":{"lat":42.10148,"lon":-72.58981}},{"facility":"Dr. Christopher Kratochvil","city":"Omaha","state":"Nebraska","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Dr. Ann Childress","city":"Las Vegas","state":"Nevada","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Dr. Melissa DelBello","city":"Cincinnati","state":"Ohio","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Dr. Leland Dennis","city":"Oklahoma City","state":"Oklahoma","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Dr. David Brown","city":"Austin","state":"Texas","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Dr. Alain Katic","city":"Bellaire","state":"Texas","country":"United States","geoPoint":{"lat":29.70579,"lon":-95.45883}},{"facility":"Dr. Graham Emslie","city":"Dallas","state":"Texas","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Dr. Mary Shemo","city":"Charlottesville","state":"Virginia","country":"United States","geoPoint":{"lat":38.02931,"lon":-78.47668}},{"facility":"Dr. John Gilliam","city":"Richmond","state":"Virginia","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Dr. Arifulla Khan","city":"Bellevue","state":"Washington","country":"United States","geoPoint":{"lat":47.61038,"lon":-122.20068}}]},"referencesModule":{"references":[{"pmid":"41938228","type":"DERIVED","citation":"Barac M, Nakonezny PA, Croarkin PE, Athreya AP, Jones SM, Hergert SM, Emslie GJ. Validation of the Brief Children's Depression Rating Scale in Children Treated With Selegiline Transdermal Patch vs Placebo. JAACAP Open. 2025 Dec 1;4(2):354-362. doi: 10.1016/j.jaacop.2025.11.010. eCollection 2026 Apr."}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Male and female adolescent subjects between 12 to 17 years of age diagnosed with moderate to severe major depressive disorder were screened over an approximate two year period at 26 investigative sites in the U.S.","groups":[{"id":"FG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"FG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"all randomized subjects who received at least one dose of placebo study medication","numSubjects":"156"},{"groupId":"FG001","comment":"all randomized subjects who received at least one dose of EMSAM study medication","numSubjects":"152"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"101"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"51"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"9"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"19"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Non-Compliance","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Other (e.g., Lack of Efficacy)","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"BG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"152"},{"groupId":"BG002","value":"308"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"152"},{"groupId":"BG002","value":"308"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14.7","spread":"1.6"},{"groupId":"BG001","value":"14.8","spread":"1.62"},{"groupId":"BG002","value":"14.8","spread":"1.61"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"93"},{"groupId":"BG002","value":"197"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"111"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"146"}]}]},{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"80"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"69"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}]},{"title":"Native American","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"SECONDARY","title":"CGI-S - Week 12 (mITT w/LOCF Population)","description":"A summary of the Clinical Global Impression of Severity (CGI-S) at baseline and Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF. The CGI-s is the clinician's assessment of severity of illness (depression). Scores range from 1(minimum) to 7(maximum). A lower score indicates lower illness severity, a higher score indicates higher levels of illness severity.","populationDescription":"Received at least one dose of placebo or EMSAM study drug, and had at least one post-treatment efficacy assessment with the primary outcome variable (CDRS-R).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and 12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"150"}]}],"classes":[{"title":"Baseline CGI-S Scale","categories":[{"measurements":[{"groupId":"OG000","value":"4.494","spread":"0.659"},{"groupId":"OG001","value":"4.527","spread":"0.662"}]}]},{"title":"Week 12 CGI-S Scale","categories":[{"measurements":[{"groupId":"OG000","value":"3.000","spread":"1.333"},{"groupId":"OG001","value":"3.007","spread":"1.250"}]}]}]},{"type":"SECONDARY","title":"CGI-C - Week 12 (mITT w/LOCF Population)","description":"A summary of the Clinicians Global Impression of Change (CGI-C) Score at Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF. The CGI-c assesses the overall change in the severity of illness (depression). The clinician rates the subject's change based on a bipolar scale from 1(minimum; \"Very much improved\") to 7(maximum; \"Very much worse\"). A lower score indicates lower levels of depression as compared to baseline, a higher score indicates higher levels of depression as compared to baseline. A score of 4 (\"Unchanged\") indicates no change in illness compared to baseline. The scale is not calculated as a statistical change score; the clinician rates their impression of change overall.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"150"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.387","spread":"1.208"},{"groupId":"OG001","value":"2.386","spread":"1.138"}]}]}]},{"type":"SECONDARY","title":"CGI-C Percent Responders (mITT w/LOCF Population)","description":"A summary of the CGI-C percent responders at Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF. CGI-C responders were defined as a score of 1 or 2 at the end of the study. A non-responder was defined as a score of ≥3 at end of study. Maximum score is 100%.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percent Responder","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"150"}]}],"classes":[{"title":"Percent Non-Responder","categories":[{"measurements":[{"groupId":"OG000","value":"40.7"},{"groupId":"OG001","value":"41.4"}]}]},{"title":"Percent Responder","categories":[{"measurements":[{"groupId":"OG000","value":"59.3"},{"groupId":"OG001","value":"58.6"}]}]}]},{"type":"SECONDARY","title":"CDRS-R Total Score (Parent/Other) Week 12 (mITT w/LOCF Population)","description":"A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Parent/Other), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time.\n\nCDRS-R (Parent/Other) total raw scores range from 14 (minimum) 94 (maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. One subscale is summed to calculate a total score: Evaluated Symptom Area. Ratings of Observed Nonverbal Behavior subscale is not included in Parent/Other total calculation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and 12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"149"}]}],"classes":[{"title":"Baseline- Observed","categories":[{"measurements":[{"groupId":"OG000","value":"49.4","spread":"11.27"},{"groupId":"OG001","value":"48.8","spread":"10.1"}]}]},{"title":"Week 12- Observed","categories":[{"measurements":[{"groupId":"OG000","value":"30.7","spread":"13.55"},{"groupId":"OG001","value":"30.5","spread":"13.36"}]}]},{"title":"Week 12 - Change From Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-18.7","spread":"14.09"},{"groupId":"OG001","value":"-18.3","spread":"14.27"}]}]}]},{"type":"SECONDARY","title":"CDRS-R Total Score (Best Description) Week 12 (mITT w/LOCF Population)","description":"A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Best Description), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time.\n\nBest Description ratings are used when ratings based on interviews with different sources (e.g., child, parent, other ratings) differ for a particular symptom. The evaluator must determine which of these ratings most accurately represents the current affective functioning of the child, and circle that rating in the Best Description of Child Column.\n\nCDRS-R (Best Description)total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"150"}]}],"classes":[{"title":"Baseline - Observed","categories":[{"measurements":[{"groupId":"OG000","value":"60.7","spread":"12.26"},{"groupId":"OG001","value":"59.5","spread":"11.05"}]}]},{"title":"Week 12 - Observed","categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":"16.62"},{"groupId":"OG001","value":"37","spread":"15.73"}]}]},{"title":"Week 12 - Change From Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-22.7","spread":"16.54"},{"groupId":"OG001","value":"-22.5","spread":"16.97"}]}]}]},{"type":"SECONDARY","title":"CDRS-R Total Score (Child) Week 12 (mITT w/OC Population)","description":"A summary of the secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Child), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population with observed cases (w/OC).\n\nCDRS-R (Child) total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"146"}]}],"classes":[{"title":"Baseline - Observed","categories":[{"measurements":[{"groupId":"OG000","value":"58.1","spread":"12.64"},{"groupId":"OG001","value":"56.6","spread":"12.39"}]}]},{"title":"Week 12 - Observed","categories":[{"measurements":[{"groupId":"OG000","value":"30.8","spread":"12.41"},{"groupId":"OG001","value":"31.1","spread":"12.38"}]}]},{"title":"Week 12 - Change From Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-25.5","spread":"15.07"},{"groupId":"OG001","value":"-25.3","spread":"15.16"}]}]}]},{"type":"SECONDARY","title":"CDRS-R Total Score (Parent/Other) Week 12 (mITT w/OC Population)","description":"A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Parent/Other), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population with observed cases (w/OC).\n\nCDRS-R (Parent/Other) total raw scores range from 14 (minimum) 94 (maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. One subscale is summed to calculate a total score: Evaluated Symptom Area. Ratings of Observed Nonverbal Behavior subscale is not included in Parent/Other total calculation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"146"}]}],"classes":[{"title":"Baseline - Observed","categories":[{"measurements":[{"groupId":"OG000","value":"49.6","spread":"11.43"},{"groupId":"OG001","value":"48.9","spread":"10.21"}]}]},{"title":"Week 12 - Observed","categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":"10.70"},{"groupId":"OG001","value":"25.8","spread":"9.59"}]}]},{"title":"Week 12 - Change From Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-22.6","spread":"12.97"},{"groupId":"OG001","value":"-22.2","spread":"12.66"}]}]}]},{"type":"SECONDARY","title":"CDRS-R Total Score (Best Description) Week 12 (mITT w/OC Population)","description":"A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Best Description), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with observed cases (w/OC).\n\nBest Description ratings are used when ratings based on interviews with different sources (e.g., child, parent, other ratings) differ for a particular symptom area. The evaluator must determine which of these ratings most accurately represents the current affective functioning of the child, and circle that rating in the Best Description of Child Column.\n\nCDRS-R (Best Description) total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"146"}]}],"classes":[{"title":"Baseline - Observed","categories":[{"measurements":[{"groupId":"OG000","value":"60.7","spread":"12.34"},{"groupId":"OG001","value":"59.4","spread":"11.10"}]}]},{"title":"Week 12 - Observed","categories":[{"measurements":[{"groupId":"OG000","value":"32.1","spread":"13.18"},{"groupId":"OG001","value":"32.4","spread":"12.75"}]}]},{"title":"Week 12 - Change From Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-27","spread":"14.93"},{"groupId":"OG001","value":"-26.6","spread":"15.18"}]}]}]},{"type":"PRIMARY","title":"CDRS-R Total Score (Child) (mITT w/LOCF Population) Week 12","description":"A summary of the primary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score, as reported by the Child, at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time.\n\nCDRS-R total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior.","populationDescription":"Received at least one dose of placebo or EMSAM study drug, and had at least one post-treatment efficacy assessment with the primary outcome variable (CDRS-R).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"baseline and 12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"150"}]}],"classes":[{"title":"Baseline - Observed","categories":[{"measurements":[{"groupId":"OG000","value":"57.9","spread":"12.57"},{"groupId":"OG001","value":"56.7","spread":"12.34"}]}]},{"title":"Week 12 - Observed","categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":"15.91"},{"groupId":"OG001","value":"35.4","spread":"15.30"}]}]},{"title":"Week 12 - Change From Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-21.5","spread":"16.47"},{"groupId":"OG001","value":"-21.4","spread":"16.61"}]}]}]},{"type":"SECONDARY","title":"Physical Examination (Screening vs. EOS)","description":"Number of physical examination findings that were normal at screening, but abnormal at end of study are presented. Four subjects receiving placebo and four subjects receiving EMSAM had abnormal findings on physical examination at the end of study that were normal at screening.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of Abnormal Exams","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"152"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Urinalysis (Change From Baseline)","description":"A summary of a secondary safety outcome measure, Urinalysis (Change from Baseline), by treatment assigned, is shown for the safety population. Mean changes from baseline are provided for PH and specific gravity.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"152"}]}],"classes":[{"title":"PH","categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.906"},{"groupId":"OG001","value":"-0.11","spread":"1.052"}]}]},{"title":"Specific Gravity","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.008"},{"groupId":"OG001","value":"0.00","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Vital Signs-Heart Rate (Change From Baseline)","description":"Summary mean change in heart rate measured in beats per minute (beats/min or BPM) (supine, standing, and orthostatic change)results for all subjects are presented.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"BPM","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"131"}]}],"classes":[{"title":"Supine Heart Rate","categories":[{"measurements":[{"groupId":"OG000","value":".20","spread":"11.90"},{"groupId":"OG001","value":"-.10","spread":"9.91"}]}]},{"title":"Standing Heart Rate","categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"14.26"},{"groupId":"OG001","value":"2.6","spread":"15.12"}]}]},{"title":"Orthostatic Change in Heart Rate","categories":[{"measurements":[{"groupId":"OG000","value":"-.80","spread":"11.70"},{"groupId":"OG001","value":"2.80","spread":"13.8"}]}]}]},{"type":"SECONDARY","title":"Vital Signs-Blood Pressure (Change From Baseline)","description":"Summary mean change in blood pressure (systolic/diastolic) measured in millimeters of mercury (mmHg) (supine, standing, and orthostatic change)results for all subjects are presented.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"131"}]}],"classes":[{"title":"Supine Systolic Blood Pressure","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"8.94"},{"groupId":"OG001","value":"-0.3","spread":"11.8"}]}]},{"title":"Supine Diastolic Blood Pressure","categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"8.21"},{"groupId":"OG001","value":"1.4","spread":"8.52"}]}]},{"title":"Standing Systolic Blood Pressure","categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"10.29"},{"groupId":"OG001","value":"-2.5","spread":"11.63"}]}]},{"title":"Standing Diastolic Blood Pressure","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"8.5"},{"groupId":"OG001","value":"-0.1","spread":"9.11"}]}]},{"title":"Orthostatic Change in Systolic Blood Pressure","categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"9.32"},{"groupId":"OG001","value":"-2.3","spread":"11.30"}]}]},{"title":"Orthostatic Change in Diastolic Blood Pressure","categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"7.84"},{"groupId":"OG001","value":"-1.5","spread":"7.85"}]}]}]},{"type":"SECONDARY","title":"12 Lead ECG (Change From Baseline)","description":"A summary of a secondary safety outcome measure, 12 Lead electrocardiogram (ECG) (Change from Baseline) measured in milliseconds (msec), by treatment assigned, is shown for the safety population. Mean change from Baseline in PR interval, QRS duration, QT interval, and QTc (Bazett and Fridericia corrections) interval are presented.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"msec","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"152"}]}],"classes":[{"title":"PR Interval","categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"10.47"},{"groupId":"OG001","value":"-0.90","spread":"11.04"}]}]},{"title":"QRS Duration","categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"5.84"},{"groupId":"OG001","value":"1.1","spread":"8.21"}]}]},{"title":"QT Interval","categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":"24.86"},{"groupId":"OG001","value":"3.80","spread":"21.51"}]}]},{"title":"QTc (Bazett Correction) Interval","categories":[{"measurements":[{"groupId":"OG000","value":"-4.10","spread":"19.20"},{"groupId":"OG001","value":"-2.90","spread":"20.23"}]}]},{"title":"QTc (Fridericia Correction) Interval","categories":[{"measurements":[{"groupId":"OG000","value":"-2.30","spread":"16.06"},{"groupId":"OG001","value":"-0.60","spread":"15.27"}]}]}]},{"type":"SECONDARY","title":"12 Lead ECG (Change From Baseline)Ventricular Heart Rate","description":"A summary of a secondary safety outcome measure, 12 Lead electrocardiogram (ECG) (Change from Baseline)Ventricular Heart Rate measured in beats per minute(beats/min or BPM), by treatment assigned, is shown for the safety population. Mean change from baseline is presented.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"BPM","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"152"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.70","spread":"10.40"},{"groupId":"OG001","value":"-2.40","spread":"10.43"}]}]}]},{"type":"SECONDARY","title":"Hematology - White Blood Cell (WBC) (Change From Baseline)","description":"A summary of a secondary safety outcome measure, Hematology (Change from Baseline), by treatment assigned, is shown for the safety population. Mean change from Baseline in ABS BASOPHILS (X10\\^9/L), ABS EOSINOPHILS (X10\\^9/L), ABS LYMPHOCYTES (X10\\^9/L), ABS MONOCYTES (X10\\^9/L), and ABS NEUTROPHILS (X10\\^9/L) are presented.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"(X10^9/L)","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"152"}]}],"classes":[{"title":"ABS BASOPHILS (X10^9/L)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.040"},{"groupId":"OG001","value":"0.00","spread":"0.035"}]}]},{"title":"ABS EOSINOPHILS (X10^9/L)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.1"},{"groupId":"OG001","value":"0.01","spread":"0.115"}]}]},{"title":"ABS LYMPHOCYTES (X10^9/L)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.535"},{"groupId":"OG001","value":"-0.03","spread":"0.538"}]}]},{"title":"ABS MONOCYTES (X10^9/L)","categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.134"},{"groupId":"OG001","value":"-0.00","spread":"0.148"}]}]},{"title":"ABS NEUTROPHILS (X10^9/L)","categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"1.542"},{"groupId":"OG001","value":"-0.10","spread":"1.346"}]}]},{"title":"PLATELETS (X10^9/L)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"44.126"},{"groupId":"OG001","value":"1.82","spread":"54.452"}]}]},{"title":"WBC (X10^9/L)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"1.813"},{"groupId":"OG001","value":"-0.12","spread":"1.614"}]}]}]},{"type":"SECONDARY","title":"Hematology - Hematocrit (Change From Baseline)","description":"A summary of a secondary safety outcome measure, Hematology - Hematocrit(HCT)(Change from Baseline), by treatment assigned, is shown for the safety population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percent","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"152"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.58","spread":"2.294"},{"groupId":"OG001","value":"-1.13","spread":"3.093"}]}]}]},{"type":"SECONDARY","title":"Hematology - Hemoglobin (Change From Baseline)","description":"A summary of a secondary safety outcome measure, Hematology - Hemoglobin(HGB)(Change from Baseline), by treatment assigned, is shown for the safety population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"g/dL","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"152"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"0.694"},{"groupId":"OG001","value":"-0.36","spread":"0.854"}]}]}]},{"type":"SECONDARY","title":"Hematology - Red Blood Cell (Change From Baseline)","description":"A summary of a secondary safety outcome measure, Hematology - Red Blood Cell (RBC)(Change from Baseline), by treatment assigned, is shown for the safety population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"x10^12/L","timeFrame":"12 Weeks","groups":[{"id":"OG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"},{"id":"OG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"152"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.234"},{"groupId":"OG001","value":"-0.12","spread":"0.313"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"12 weeks","eventGroups":[{"id":"EG000","title":"Placebo","description":"Placebo Selegiline Transdermal System 6, 9 or 12\n\nPlacebo : Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study","seriousNumAffected":3,"seriousNumAtRisk":156,"otherNumAffected":90,"otherNumAtRisk":156},{"id":"EG001","title":"EMSAM","description":"Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg\n\nSelegiline Transdermal System : EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study","seriousNumAffected":7,"seriousNumAtRisk":152,"otherNumAffected":95,"otherNumAtRisk":152}],"seriousEvents":[{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":156},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":152}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":156},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":152}]},{"term":"Loss of Consciousness","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":156},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":152}]},{"term":"Mood Swings","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":156},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":152}]},{"term":"Orthstatic Hypotension","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":156},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":152}]},{"term":"Psychotic Disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":156},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":152}]},{"term":"Screaming","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":156},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":152}]},{"term":"Suicidal Ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":156},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":152}]},{"term":"Syncope","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":156},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":152}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":156},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":152}]}],"otherEvents":[{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":156},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":152}]},{"term":"Abdominal Pain Upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":156},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":152}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":156},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":152}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":156},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":152}]},{"term":"Application Site Reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":34,"numAtRisk":156},{"groupId":"EG001","numEvents":37,"numAffected":37,"numAtRisk":152}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":156},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":152}]},{"term":"Decreased Appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":156},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":152}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":156},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":152}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":156},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":152}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":156},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":152}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":26,"numAtRisk":156},{"groupId":"EG001","numEvents":26,"numAffected":26,"numAtRisk":152}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":156},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":152}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":156},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":152}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":156},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":152}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":156},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":152}]},{"term":"Pharyngolaryngeal Pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":156},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":152}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":156},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":152}]},{"term":"Suicidal Ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":156},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":152}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":156},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":152}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":156},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":152}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Investigator is free to publish for their own research or publication objectives, provided that such does not disclose Confidential Information. At least 45 days prior the Investigator shall submit for Sponsor review. Sponsor will advise of revisions necessary to preserve confidential and proprietary information. The first publication of the results shall be a joint Multi-Center publication of results with the investigators from all study sites contributing data."},"pointOfContact":{"title":"Kim Portland, Ph.D.","organization":"Mylan Specialty L.P.","email":"kimberly.portland@mylan.com","phone":"908.542.2636"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D003865","term":"Depressive Disorder, Major"},{"id":"D000092862","term":"Psychological Well-Being"},{"id":"D003863","term":"Depression"}],"ancestors":[{"id":"D003866","term":"Depressive Disorder"},{"id":"D019964","term":"Mood Disorders"},{"id":"D001523","term":"Mental Disorders"},{"id":"D010549","term":"Personal Satisfaction"},{"id":"D001519","term":"Behavior"},{"id":"D001526","term":"Behavioral Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D012642","term":"Selegiline"}],"ancestors":[{"id":"D010627","term":"Phenethylamines"},{"id":"D005021","term":"Ethylamines"},{"id":"D000588","term":"Amines"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}